Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of D-0120 in Healthy Volunteers
NCT04097405Phase 1Completed
- Sponsor
- InventisBio
- Start
- Sep 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of darbinurad in hyperuricemia and gout (3 arms), sponsored by InventisBio. Primary endpoint: Number of subjects with treatment related adverse events at 16 days. Started Sep 2019; status: completed.
02
Drugs
darbinurad
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT04097405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04097405.